Pasar al contenido principal

DESARROLLO DE NUEVAS HERRAMIENTAS FARMACOLOGICAS ANTITUMORALES QUE DIRIJAN SU ACCION AL SILENCIAMIENTO O A LA INHIBICION DE LA MAP KINASA ERK5

SAF2015-64237-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Villafranca-Magdalena, Beatriz|||0000-0001-9921-919X
  • Viñas-Casas, Maria|||0000-0003-1438-7325
  • Gamez-Garcia, Andrés|||0000-0003-4927-3678
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Ivanova, Saska
  • Denizli, Melek|||0000-0002-9325-2535
  • Faúndez Vidiella, Claudia
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies. {'@id': 'Par2', 'graphic': {'@position': 'anchor', '@xlink:href': '41419_2023_6229_Figa_HTML', '@id': 'd32e443'}}.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio
  • Ivanova, Saska
  • Alari-Pahissa, Elisenda
  • Denizli, Melek
  • Villafranca-Magdalena, Beatriz
  • Viñas-Casas, Maria
  • Bolinaga-Ayala, Idoia
  • Gámez-García, Andrés
  • Faundez-Vidiella, Claudia
  • Colas, Eva
  • López-Botet, M. (Miguel)
  • Zorzano, Antonio
  • Lizcano, José Miguel
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies., SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

The ERK5/NF‑κB signaling pathway targets endometrial cancer proliferation and survival

  • Diéguez‑Martínez, Nora
  • Espinosa‑Gil, Sergio
  • Yoldi, Guillermo
  • Gorgisen, Gokhan
  • Domingo Ortí, Inés
  • Viñas Casas, Maria
  • Bolinaga Ayala, Idoia
  • Megías Roda, Elisabet
  • Pérez‑Montoyo, Héctor
  • José Ramón, Bayascas Ramírez
  • Colás, Eva
  • Dolcet Roca, Xavier
  • Lizcano, José M.
Endometrial cancer (EC) is the most common type of gynecologic cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with high-risk EC tumors is poor, indicating a need for novel therapies. The MEK5-ERK5 pathway is activated in response to growth factors and to different stressors, including oxidative stress and cytokines. Previous evidence supports a role for the MEK5-ERK5 pathway in the pathology of several cancers. We investigated the role of ERK5 in EC. In silico analysis of the PanCancer Atlas dataset showed alterations in components of the MEK5-ERK5 pathway in 48% of EC patients. Here, we show that ERK5 inhibition or silencing decreased EGF-induced EC cell proliferation, and that genetic deletion of MEK5 resulted in EC impaired proliferation and reduced tumor growth capacity in nude mice. Pharmacologic inhibition or ERK5 silencing impaired NF-kB pathway in EC cells and xenografts. Furthermore, we found a positive correlation between ERK5 and p65/RELA protein levels in human EC tumor samples. Mechanistically, genetic or pharmacologic impairment of ERK5 resulted in downregulation of NEMO/ IKKγ expression, leading to impaired p65/RELA activity and to apoptosis in EC cells and xenografts, which was rescued by NEMO/IKKγ overexpression. Notably, ERK5 inhibition, MEK5 deletion or NF-kB inhibition sensitized EC cells to standard EC chemotherapy (paclitaxel/carboplatin) toxicity, whereas ERK5 inhibition synergized with paclitaxel to reduce tumor xenograft growth in mice. Together, our results suggest that the ERK5-NEMO-NF-κB pathway mediates EC cell proliferation and survival. We propose the ERK5/NF-κB axis as new target for EC treatment., Open Access Funding provided by Universitat Autonoma de Barcelona. The JM Lizcano research group was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO, grant SAF2015-64237-R), and the Spanish Ministry of Science and Innovation (grant PID2019-107561RB-I00), and co-funded by the European Regional Development Fund (ERDF).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

  • Muñoz-Guardiola, Pau
  • Casas, Josefina
  • Megías-Roda, Elisabet
  • Solé, Sonia
  • Perez-Montoyo, Héctor
  • Yeste-Velasco, Marc
  • Erazo, Tatiana
  • Dièguez-Martínez, Nora
  • Espinosa-Gil, Sergio
  • Muñoz-Pinedo, Cristina
  • Yoldi, Guillermo
  • Abad, José Luis
  • Segura, Miguel F.
  • Moran, Teresa
  • Romeo, Margarita
  • Bosch-Barrera, Joaquim
  • Oaknin, Ana
  • Alfón, Jose
  • Domènech, Carles
  • Fabriàs, Gemma
  • Velasco, Guillermo
  • Lizcano, José M.
ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed that ABTL0812 induces TRIB3 pseudokinase expression, resulting in the inhibition of the AKT-MTORC1 axis and macroautophagy/autophagy-mediated cancer cell death. However, the precise molecular determinants involved in the cytotoxic autophagy caused by ABTL0812 remained unclear. Using a wide range of biochemical and lipidomic analyses, we demonstrated that ABTL0812 increases cellular long-chain dihydroceramides by impairing DEGS1 (delta 4-desaturase, sphingolipid 1) activity, which resulted in sustained ER stress and activated unfolded protein response (UPR) via ATF4-DDIT3-TRIB3 that ultimately promotes cytotoxic autophagy in cancer cells. Accordingly, pharmacological manipulation to increase cellular dihydroceramides or incubation with exogenous dihydroceramides resulted in ER stress, UPR and autophagy-mediated cancer cell death. Importantly, we have optimized a method to quantify mRNAs in blood samples from patients enrolled in the ongoing clinical trial, who showed significant increased DDIT3 and TRIB3 mRNAs. This is the first time that UPR markers are reported to change in human blood in response to any drug treatment, supporting their use as pharmacodynamic biomarkers for compounds that activate ER stress in humans. Finally, we found that MTORC1 inhibition and dihydroceramide accumulation synergized to induce autophagy and cytotoxicity, phenocopying the effect of ABTL0812. Given the fact that ABTL0812 is under clinical development, our findings support the hypothesis that manipulation of dihydroceramide levels might represents a new therapeutic strategy to target cancer., This work was supported by the Centre for Industrial Technological Development [CDTI,INNOGLOBAL/20171061]; European Regional Development Fund [PI18/00442 and PI15/00339]; European Regional Development Fund [INNPACTO/IPT-2012-0614-010000, RETOS RTC-2017-6261-1, SAF2015-64237-R]; Fundació la Marató de TV3 [20134031]; H2020 Marie Skłodowska-Curie Actions [TRAIN GA721532]; Instituto de Salud Carlos III [PI15/00339]; Instituto de Salud Carlos III [PI18/00442]; Ministerio de Ciencia, Innovación y Universidades [CTQ2017- 85378-R]; Ministerio de Economía y Competitividad [RTC-2015-3821-1]; Ministerio de Economía y Competitividad [RTC-2017-6261-1]; Ministerio de Economía y Competitividad [EMP-TU-2015-4576]; Ministerio de Economía y Competitividad [RETOS RTC-2017-6261-1]; Ministerio de Economía y Competitividad [BFU2016-78154-R]; Ministerio de Economía y Competitividad [INNPACTO/IPT-2012-0614-010000]; Ministerio de Economía y Competitividad [SAF2015-64237-R]; Ministerio de Economía y Competitividad [RTC-2014-1532-1]., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The ERK5/NF‑κB signaling pathway targets endometrial cancer proliferation and survival

  • Diéguez‑Martínez, Nora
  • Espinosa‑Gil, Sergio
  • Yoldi, Guillermo
  • Gorgisen, Gokhan
  • Domingo Ortí, Inés
  • Viñas Casas, Maria
  • Bolinaga Ayala, Idoia
  • Megías Roda, Elisabet
  • Pérez‑Montoyo, Héctor
  • José Ramón, Bayascas Ramírez
  • Colás, Eva
  • Dolcet Roca, Xavier
  • Lizcano, José M.
Endometrial cancer (EC) is the most common type of gynecologic cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with high-risk EC tumors is poor, indicating a need for novel therapies. The MEK5-ERK5 pathway is activated in response to growth factors and to different stressors, including oxidative stress and cytokines. Previous evidence supports a role for the MEK5-ERK5 pathway in the pathology of several cancers. We investigated the role of ERK5 in EC. In silico analysis of the PanCancer Atlas dataset showed alterations in components of the MEK5-ERK5 pathway in 48% of EC patients. Here, we show that ERK5 inhibition or silencing decreased EGF-induced EC cell proliferation, and that genetic deletion of MEK5 resulted in EC impaired proliferation and reduced tumor growth capacity in nude mice. Pharmacologic inhibition or ERK5 silencing impaired NF-kB pathway in EC cells and xenografts. Furthermore, we found a positive correlation between ERK5 and p65/RELA protein levels in human EC tumor samples. Mechanistically, genetic or pharmacologic impairment of ERK5 resulted in downregulation of NEMO/ IKKγ expression, leading to impaired p65/RELA activity and to apoptosis in EC cells and xenografts, which was rescued by NEMO/IKKγ overexpression. Notably, ERK5 inhibition, MEK5 deletion or NF-kB inhibition sensitized EC cells to standard EC chemotherapy (paclitaxel/carboplatin) toxicity, whereas ERK5 inhibition synergized with paclitaxel to reduce tumor xenograft growth in mice. Together, our results suggest that the ERK5-NEMO-NF-κB pathway mediates EC cell proliferation and survival. We propose the ERK5/NF-κB axis as new target for EC treatment., Open Access Funding provided by Universitat Autonoma de Barcelona. The JM Lizcano research group was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO, grant SAF2015-64237-R), and the Spanish Ministry of Science and Innovation (grant PID2019-107561RB-I00), and co-funded by the European Regional Development Fund (ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio
  • Ivanova, Saska
  • Alari-Pahissa, Elisenda
  • Denizli, Melek
  • Villafranca-Magdalena, Beatriz
  • Viñas-Casas, Maria
  • Bolinaga-Ayala, Idoia
  • Gámez-García, Andrés
  • Faundez-Vidiella, Claudia
  • Colas, Eva
  • López-Botet, M. (Miguel)
  • Zorzano, Antonio
  • Lizcano, José Miguel
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies., SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ERK5 and Cell Proliferation, Nuclear Localization Is What Matters

  • Gomez, Nestor|||0000-0002-1348-2737
  • Erazo, Tatiana|||0000-0003-2355-0999
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
ERK5, the last MAP kinase family member discovered, is activated by the upstream kinase MEK5 in response to growth factors and stress stimulation. MEK5-ERK5 pathway has been associated to different cellular processes, playing a crucial role in cell proliferation in normal and cancer cells by mechanisms that are both dependent and independent of its kinase activity. Thus, nuclear ERK5 activates transcription factors by either direct phosphorylation or acting as co-activator thanks to a unique transcriptional activation TAD domain located at its C-terminal tail. Consequently, ERK5 has been proposed as an interesting target to tackle different cancers, and either inhibitors of ERK5 activity or silencing the protein have shown antiproliferative activity in cancer cells and to block tumor growth in animal models. Here, we review the different mechanisms involved in ERK5 nuclear translocation and their consequences. Inactive ERK5 resides in the cytosol, forming a complex with Hsp90-Cdc37 superchaperone. In a canonical mechanism, MEK5-dependent activation results in ERK5 C-terminal autophosphorylation, Hsp90 dissociation, and nuclear translocation. This mechanism integrates signals such as growth factors and stresses that activate the MEK5-ERK5 pathway. Importantly, two other mechanisms, MEK5-independent, have been recently described. These mechanisms allow nuclear shuttling of kinase-inactive forms of ERK5. Although lacking kinase activity, these forms activate transcription by interacting with transcription factors through the TAD domain. Both mechanisms also require Hsp90 dissociation previous to nuclear translocation. One mechanism involves phosphorylation of the C-terminal tail of ERK5 by kinases that are activated during mitosis, such as Cyclin-dependent kinase-1. The second mechanism involves overexpression of chaperone Cdc37, an oncogene that is overexpressed in cancers such as prostate adenocarcinoma, where it collaborates with ERK5 to promote cell proliferation. Although some ERK5 kinase inhibitors have shown antiproliferative activity it is likely that those tumors expressing kinase-inactive nuclear ERK5 will not respond to these inhibitors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SUMOylation Is Required for ERK5 Nuclear Translocation and ERK5-Mediated Cancer Cell Proliferation

  • Erazo, Tatiana|||0000-0003-2355-0999
  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Diéguez-Martínez, Nora|||0000-0002-5366-4543
  • Gomez, Nestor|||0000-0002-1348-2737
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
The MAP kinase ERK5 contains an N-terminal kinase domain and a unique C-terminal tail including a nuclear localization signal and a transcriptional activation domain. ERK5 is activated in response to growth factors and stresses and regulates transcription at the nucleus by either phosphorylation or interaction with transcription factors. MEK5-ERK5 pathway plays an important role regulating cancer cell proliferation and survival. Therefore, it is important to define the precise molecular mechanisms implicated in ERK5 nucleo-cytoplasmic shuttling. We previously described that the molecular chaperone Hsp90 stabilizes and anchors ERK5 at the cytosol and that ERK5 nuclear shuttling requires Hsp90 dissociation. Here, we show that MEK5 or overexpression of Cdc37-mechanisms that increase nuclear ERK5-induced ERK5 Small Ubiquitin-related Modifier (SUMO)-2 modification at residues Lys6/Lys22 in cancer cells. Furthermore, mutation of these SUMO sites abolished the ability of ERK5 to translocate to the nucleus and to promote prostatic cancer PC-3 cell proliferation. We also show that overexpression of the SUMO protease SENP2 completely abolished endogenous ERK5 nuclear localization in response to epidermal growth factor (EGF) stimulation. These results allow us to propose a more precise mechanism: in response to MEK5 activation, ERK5 SUMOylation favors the dissociation of Hsp90 from the complex, allowing ERK5 nuclear shuttling and activation of the transcription.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis

  • París-Coderch, Laia|||0000-0003-2145-5752
  • Soriano, Aroa|||0000-0001-9659-1471
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Erazo, Tatiana|||0000-0003-2355-0999
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Masanas, Marc|||0000-0002-2249-8554
  • Antonelli, Roberta|||0000-0001-6884-7847
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Alfón, José|||0000-0002-1874-0184
  • Pérez-Montoyo, Héctor|||0000-0002-9540-9604
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Domenech, Carles|||0000-0002-2817-3750
  • Roma, Josep|||0000-0001-7692-6123
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
Neuroblastoma is the leading cause of cancer death in children aged 1 to 4 years. Particularly, five-year overall survival for high-risk neuroblastoma is below 50% with no curative options when refractory or relapsed. Most of current therapies target cell division and proliferation, thereby inducing DNA damage and programmed cell death. However, aggressive tumours often present alterations of these processes and are resistant to therapy. Therefore, exploring alternative pathways to induce tumour cell death will provide new therapeutic opportunities for these patients. In this study we aimed at testing the therapeutic potential of ABTL0812, a novel anticancer drug that induces cytotoxic autophagy to eliminate cancer cells, which is currently in phase II clinical trials of adult tumours. Here, we show that ABTL0812 impaired the viability of clinical representative neuroblastoma cell lines regardless of genetic alterations associated to bad prognosis and resistance to therapy. Oral administration of ABTL0812 to mice bearing neuroblastoma xenografts impaired tumour growth. Furthermore, our findings revealed that, in neuroblastoma, ABTL0812 induced cancer cell death via induction of endoplasmic reticulum stress, activation of the unfolded protein response, autophagy and apoptosis. Remarkably, ABTL0812 potentiated the antitumour activity of chemotherapies and differentiating agents such as irinotecan and 13 -cis -retinoic acid. In conclusion, ABTL0812 distinctive mechanism of action makes it standout to be used alone or in combination in high-risk neuroblastoma patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival

  • Diéguez-Martínez, Nora|||0000-0002-5366-4543
  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Yoldi Salinas, Guillermo
  • Megías-Roda, Elisabet|||0000-0001-7858-2168
  • Bolinaga Ayala, Idoia|||0000-0002-6308-3646
  • Viñas-Casas, Maria|||0000-0003-1438-7325
  • Gorgisen, Gokhan|||0000-0001-6040-7863
  • Domingo-Ortí, Inés|||0000-0003-4959-4914
  • Pérez-Montoyo, Héctor|||0000-0002-9540-9604
  • Bayascas Ramírez, José Ramón|||0000-0002-6096-2151
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Dolcet, Xavier|||0000-0003-1921-0449
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
Endometrial cancer (EC) is the most common type of gynecologic cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with high-risk EC tumors is poor, indicating a need for novel therapies. The MEK5-ERK5 pathway is activated in response to growth factors and to different stressors, including oxidative stress and cytokines. Previous evidence supports a role for the MEK5-ERK5 pathway in the pathology of several cancers. We investigated the role of ERK5 in EC. In silico analysis of the PanCancer Atlas dataset showed altera- tions in components of the MEK5-ERK5 pathway in 48% of EC patients. Here, we show that ERK5 inhibition or silencing decreased EGF-induced EC cell proliferation, and that genetic deletion of MEK5 resulted in EC impaired proliferation and reduced tumor growth capacity in nude mice. Pharmacologic inhibition or ERK5 silencing impaired NF-kB pathway in EC cells and xenografts. Furthermore, we found a positive correlation between ERK5 and p65/RELA protein levels in human EC tumor samples. Mechanistically, genetic or pharmacologic impairment of ERK5 resulted in downregulation of NEMO/ IKKγ expression, leading to impaired p65/RELA activity and to apoptosis in EC cells and xenografts, which was rescued by NEMO/IKKγ overexpression. Notably, ERK5 inhibition, MEK5 deletion or NF-kB inhibition sensitized EC cells to standard EC chemotherapy (paclitaxel/carboplatin) toxicity, whereas ERK5 inhibition synergized with paclitaxel to reduce tumor xenograft growth in mice. Together, our results suggest that the ERK5-NEMO-NF-κB pathway mediates EC cell prolifera- tion and survival. We propose the ERK5/NF-κB axis as new target for EC treatment.The online version contains supplementary material available at 10.1007/s00018-022-04541-6.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ERK5 Inhibition Induces Autophagy-Mediated Cancer Cell Death by Activating ER Stress

  • Gámez-García, Andrés
  • Bolinaga Ayala, Idoia|||0000-0002-6308-3646
  • Yoldi Salinas, Guillermo
  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Diéguez-Martínez, Nora|||0000-0002-5366-4543
  • Megías-Roda, Elisabet|||0000-0001-7858-2168
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
Autophagy is a highly conserved intracellular process that preserves cellular homeostasis by mediating the lysosomal degradation of virtually any component of the cytoplasm. Autophagy is a key instrument of cellular response to several stresses, including endoplasmic reticulum (ER) stress. Cancer cells have developed high dependency on autophagy to overcome the hostile tumor microenvironment. Thus, pharmacological activation or inhibition of autophagy is emerging as a novel antitumor strategy. ERK5 is a novel member of the MAP kinase family that is activated in response to growth factors and different forms of stress. Recent work has pointed ERK5 as a major player controlling cancer cell proliferation and survival. Therefore small-molecule inhibitors of ERK5 have shown promising therapeutic potential in different cancer models. Here, we report for the first time ERK5 as a negative regulator of autophagy. Thus, ERK5 inhibition or silencing induced autophagy in a panel of human cancer cell lines with different mutation patterns. As reported previously, ERK5 inhibitors (ERK5i) induced apoptotic cancer cell death. Importantly, we found that autophagy mediates the cytotoxic effect of ERK5i, since ATG5 ˉ / ˉ autophagy-deficient cells viability was not affected by these compounds. Mechanistically, ERK5i stimulated autophagic flux independently of the canonical regulators AMPK or mTORC1. Moreover, ERK5 inhibition resulted in ER stress and activation of the Unfolded Protein Response (UPR) pathways. Specifically, ERK5i induced expression of the ER luminal chaperone BiP (a hallmark of ER stress), the UPR markers CHOP and ATF4, and the spliced form of XBP1. Pharmacological inhibition of UPR with chemical chaperone TUDC, or ATF4 silencing, resulted in impaired ERK5i-mediated UPR, autophagy and cytotoxicity. Overall, our results suggest that ERK5 inhibition induces autophagy-mediated cancer cell death by activating ER stress. Since ERK5 inhibition sensitizes cancer cells and tumors to chemotherapy, future work will determine the relevance of UPR and autophagy in the combined use of chemotherapy and ERK5i to tackle Cancer.